CNMD · XBRL financial data

CONMED financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CNMD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	305	327*	312	332	317	346*	321	342	338	373*	343	336
Revenue from contracts with customers	305	327*	312	332	317	346*	321	342	338	373*	343	336
Cost of goods and services sold	137	145*	140	148	138	148*	144	154	172	155*	146	146
Gross profit	168	182*	172	184	179	198*	178	188	166	218*	197	189
Research and development	12	14*	14	14	14	13*	13	14	14	15*	16	16
Selling, general and administrative	125	118*	123	123	100	133*	149	136	140	167*	146	136
General and administrative	—	year only	32	29	28	28*	33	33	32	34*	31	—
Total operating expenses	138	132*	137	137	113	146*	162	150	154	182*	161	152
Operating income (loss)	30	50*	35	47	66	52*	16	38	12	37*	36	37
Interest expense	10	10*	10	10	9	9*	8	8	8	7*	8	11
Other income (expense)	—	—	—	—	—	—	—	(0)	0	—	3	0
Income tax expense (benefit)	4	8*	6	8	7	10*	2	8	1	13*	8	6
Net income (loss)	16	33*	20	30	49	34*	6	21	3	17*	23	20
Earnings per share, basic USD per share	0.52	1.08*	0.64	0.97	1.59	1.09*	0.19	0.69	0.09	0.54*	0.77	0.66
Earnings per share, diluted USD per share	0.50	1.05*	0.63	0.96	1.57	1.08*	0.19	0.69	0.09	0.53*	0.77	0.66
Weighted average shares, basic millions of shares	31	31*	31	31	31	31*	31	31	31	31*	30	30
Weighted average shares, diluted millions of shares	32	31*	31	31	31	31*	31	31	31	31*	30	30

Fiscal quarters (CNMD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	31	24	34	29	38	24	35	34	39	41	37	48
Accounts receivable	230	242	241	239	231	238	221	234	225	248	240	234
Inventory	326	318	322	322	343	347	355	362	364	356	360	363
Prepaid and other current assets	39	31	38	33	29	31	28	27	34	29	38	37
Total current assets	626	616	636	624	641	640	639	658	662	673	676	682
Property and equipment, net	120	121	118	117	117	116	116	117	112	113	110	109
Right-of-use asset	—	17	—	—	—	40	—	—	—	49	—	—
Goodwill	815	807	806	806	807	805	806	807	807	807	797	797
Total assets	2,326	2,300	2,309	2,286	2,316	2,306	2,298	2,328	2,322	2,326	2,300	2,304
Accounts payable	82	88	102	101	105	102	96	101	107	94	101	98
Total current liabilities	376	311	291	266	282	278	283	295	315	315	455	459
Lease liability, non-current	—	10	—	—	—	33	—	—	—	44	—	—
Total liabilities	1,529	1,466	1,455	1,404	1,383	1,344	1,320	1,326	1,314	1,293	1,259	1,245
Retained earnings	426	453	466	490	533	560	560	575	572	589	626	645
Total stockholders' equity	796	834	855	882	933	963	978	1,003	1,008	1,033	1,041	1,060
Total liabilities and equity	2,326	2,300	2,309	2,286	2,316	2,306	2,298	2,328	2,322	2,326	2,300	2,304
Common shares outstanding (cover page) millions of shares	31	31	31	31	31	31	31	31	31	31	30	30

Fiscal quarters (CNMD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	16	33*	20	30	49	34*	6	21	3	17*	23	20
Stock-based compensation	6*	6*	6	7	6	6*	14	5	5	5*	5	6*
Net cash from operating activities	46*	56*	29	43*	51*	43*	42	29*	54*	46*	—	49*
Purchases of property and equipment	5*	5*	2	4*	3*	4*	4	6*	5*	5*	—	3*
Net cash from investing activities	(5)*	(5)*	(2)	(4)*	(3)*	(4)*	(3)	(6)*	(5)*	(7)*	—	(2)*
Share repurchases	—	—	—	—	—	—	—	—	0*	—	—	6*
Dividends paid	6*	6*	6	6*	6*	6*	6	6*	6*	6*	—	0*
Net cash from financing activities	(37)*	(59)*	(17)	(44)*	(39)*	(51)*	(28)	(27)*	(44)*	(37)*	—	(37)*
Net change in cash	3*	(6)*	10	(5)*	10*	(14)*	11	(2)*	5*	2*	—	11*

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
CONMED	48	336	49*	29.8M	—	Q3 FY26 10-QSep 30, 2026
Alphatec Holdings	80	221	19*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Tandem Diabetes Care	63	255	(35)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Artivion	77	126	(1.3)*	48.8M	61.1 quarters	Q2 FY26 10-QJun 30, 2026
NovoCure	97	193	23	116.9M	—	Q3 FY26 10-QSep 30, 2026
Establishment Labs Holdings	71	68	(17)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Integra Lifesciences Holdings	252	411	96*	77.8M	—	Q3 FY26 10-QSep 30, 2026
AtriCure	168	154	22*	50.9M	—	Q2 FY26 10-QJun 30, 2026
Lemaitre Vascular	27	not reported	16*	22.9M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.